Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
CLPT Catalyst Timeline
Dated clinical, regulatory and corporate events for ClearPoint Neuro Inc.
Past FDA Catalysts and PDUFA Decisions
How CLPT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
ClearPoint Neuro Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CLPT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BURNETT JOSEPHDirector, Officer (CEO and President) | Option | 12,517 130,720 held | $3.47 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CLPT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CLPT for Q3 2026. | ||||
Ownership Trends
CLPT Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How CLPT ranks across every disease it competes in
CLPT News
ClearPoint Neuro Reports Third Quarter 2026 Results
ClearPoint Neuro reported a 36% increase in revenue for Q3 2026, totaling $12.1 million. The growth was driven by a 59% rise in neurosurgery navigation and therapy revenue. The company is optimistic about its product pipeline and has a cash balance of $46.2 million. Revenue guidance for 2026 is projected between $48.0 million and $50.0 million.
Read more →ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026
ClearPoint Neuro, Inc. will release its financial results for the third quarter of 2026 on October 28, 2026, after market close. A live broadcast of the results will be available for investors and analysts, with a replay option thereafter. The company continues to operate in multiple regions, offering innovative solutions in brain and spine navigation.
Read more →ClearPoint Neuro Reports Second Quarter 2026 Results
ClearPoint Neuro reported second quarter 2026 revenue of $10.9 million, an 18% increase. However, the Biologics and Drug Delivery segment saw a 15% decline due to fewer products shipped. Positive FDA feedback on partner submissions suggests potential commercial availability of new therapies by 2027. The company anticipates significant clinical trial activity in the coming months.
Read more →ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
ClearPoint Neuro congratulated Aspen Neuroscience for receiving RMAT designation from the FDA for sasineprocel, an autologous cell replacement therapy for Parkinson's disease. This designation facilitates an expedited development and review process. ClearPoint's navigation system has been utilized in the ASPIRO trial, which evaluates sasineprocel's effectiveness in treating moderate to severe Parkinson's disease.
Read more →ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026
ClearPoint Neuro, Inc. will release its financial results for the second quarter of 2026 on August 3, 2026, after market close. A live conference call will occur at 4:30 p.m. Eastern time, with access available online and via telephone. A replay will be available until September 2, 2026.
Read more →ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro has announced a 10-year partnership with Sungkyunkwan University to develop focused ultrasound technology for drug delivery. This follows a successful proof-of-concept trial demonstrating the delivery of large molecules across the blood-brain barrier. The collaboration aims to enhance ClearPoint's drug delivery ecosystem and expand its global footprint in neuro navigation and therapy.
Read more →ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro announced that its Velocity Alpha MR High Speed Surgical Drill System has received CE Marking, complementing its existing FDA 510(k) clearance. This drill is designed to improve efficiency in neurosurgical procedures and integrates with the company's SmartFrame navigation platform. The approval supports ClearPoint's strategy to expand its product portfolio and enhance global operations.
Read more →ClearPoint Neuro Reports First Quarter 2026 Results
ClearPoint Neuro reported strong financial growth in the first quarter of 2026, achieving record revenues of $12.1 million, representing a 43% increase year-over-year. The company experienced a 25% organic growth in its devices segment and expansion in its global installed base to over 175 centers. Despite the positive performance, operating expenses rose significantly, reflecting higher costs associated with company growth, while cash reserves decreased compared to the previous quarter. ClearPoint remains optimistic about continued progress across its core growth strategies and achieving future revenue targets.
Read more →ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026
ClearPoint Neuro, Inc. will release its financial results for the first quarter of 2026 on May 13, after market close. Investors can participate in a live broadcast at 4:30 p.m. Eastern time. A replay will be available until June 12, 2026, for those unable to attend the live session.
Read more →ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro announced FDA clearance of its Velocity Alpha MR High Speed Surgical Drill System, following its first clinical use. This drill enhances procedural efficiency and is designed for complex neurosurgical applications. It integrates with the SmartFrame navigation platform and aims to support a broader range of therapeutic workflows.
Read more →ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro has announced the receipt of a Medical Device License from Health Canada for its Neuro Navigation System. This approval enhances the company's drug delivery ecosystem and allows Canadian neurosurgery centers to utilize their advanced image-guidance workflows. The integration of Canadian clinical trial sites into ClearPoint's global infrastructure aims to streamline processes and support the goal of enabling 20,000 cell and gene therapy procedures annually.
Read more →ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results Record Revenue and IRRAS Holdings Acquisition Highlight the Company's ‘Fast. Forward.' Strategy
ClearPoint Neuro, Inc. reported a record revenue of $10.4 million in the fourth quarter of 2025, marking a 34% growth compared to the previous year. The successful acquisition of IRRAS Holdings has expanded the company’s portfolio into neurocritical care, enabling access to a new market. Overall revenue for 2025 reached $37.0 million, indicating consistent growth over the past eleven years. The company expects continued expansion, projecting revenues between $52.0 - $56.0 million for 2026, while addressing increased operating expenses resulting from the acquisition and development efforts.
Read more →ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe
ClearPoint Neuro has received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2, allowing it to offer a unified navigation platform in Europe. This new version enhances surgical capabilities by introducing an intraoperative CT workflow, making precision-guided neurosurgery more accessible. The software aims to reduce operational costs and improve training consistency across global markets.
Read more →ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
ClearPoint Neuro, Inc. announced preliminary unaudited revenue growth for Q4 2025, reporting approximately $10.4 million, a 20% increase compared to Q4 2024. The company expects continued expansion in its four growth markets for 2026, projecting total revenues between $54 million and $60 million. The results are preliminary and subject to revision after the annual audit, highlighting potential uncertainties in future performance. ClearPoint is focused on integrating its recent acquisition of the IRRAflow product line, which is expected to contribute to growth.
Read more →ClearPoint Neuro Completes Acquisition of IRRAS Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation
ClearPoint Neuro has successfully completed its acquisition of IRRAS Holdings, enhancing its capabilities in CNS drug delivery. The $5 million cash transaction involved the issuance of shares and outlines a revenue share model on certain sales. With the debut of the IRRAflow technology, ClearPoint aims to strengthen its position in neurocritical care. The merger is viewed as a strategic move to expand market reach and improve patient-centric services.
Read more →ClearPoint Neuro Reports Third Quarter 2025 Results Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization
ClearPoint Neuro reported its third-quarter financial results for 2025, highlighting a revenue increase of 9% compared to the previous year. The company is enhancing its capabilities with the opening of a new pre-clinical facility and has received FDA clearance for its Laser Therapy System, broadening market access. ClearPoint also announced plans to acquire IRRAS Holdings, which will expand its offerings in neurocritical care. The firm aims to support more cell and gene therapy trials by activating additional specialized treatment centers.
Read more →ClearPoint Neuro Announces Agreement to Acquire IRRAS
ClearPoint Neuro has announced an agreement to acquire IRRAS Holdings, which specializes in neurocritical care technologies. This acquisition aims to expand ClearPoint's drug delivery portfolio and gain access to a global market estimated at $0.5 billion for the treatment of intracranial bleeding. The deal is expected to enhance operational scale and includes a cash payment along with shares of ClearPoint common stock. Completion of the merger is contingent upon IRRAS shareholder approval, with expectations of significant revenue growth for 2026.
Read more →ClearPoint Neuro Reports Second Quarter 2025 Results Record Revenue and Substantial Cash Infusion Highlight the Company's ‘Fast. Forward.' Strategy
ClearPoint Neuro reported record financial results for the second quarter of 2025, achieving $9.2 million in revenue, which represents a 17% increase compared to the same quarter last year. The company experienced significant growth in neurosurgery navigation and therapy revenue, driven by new product offerings. ClearPoint also secured a substantial cash infusion through a note financing arrangement and a stock purchase agreement, ultimately enhancing its cash reserves to $41.5 million. Despite positive financial results, there was a slight decrease in gross margin and an increase in operating expenses.
Read more →ClearPoint Neuro Reports First Quarter 2025 Results
ClearPoint Neuro, Inc. reported a record revenue of $8.5 million for the first quarter of 2025, marking an 11% increase from the same period in 2024. The company experienced significant growth in its single-use navigation and therapy products, with a notable 70% increase in neurosurgery revenue. Additionally, ClearPoint received FDA clearance for its new software, now available in the market, which is driving revenue and usage growth. Despite increased operating expenses and a decline in cash reserves, the company remains optimistic about its financial outlook for the year.
Read more →ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results
ClearPoint Neuro, Inc. reported its fourth quarter and full year 2024 results, achieving record revenue of $31.4 million, marking a 31% growth compared to 2023. The company also noted a significant decrease in operational cash burn by 35%, reflecting improved financial management. Key highlights included the activation of 25 new global centers, further supporting their clinical trials and partnerships. Despite increased operating expenses due to higher personnel costs, ClearPoint remains optimistic about future growth and upcoming product launches. They project continued revenue growth for 2025, estimating between $36 million and $41 million.
Read more →